JOHNSON & JOHNSON is expected to release its Q3 2026 10-Q filing on October 13, 2026. Last quarter: JNJ reported Q2 FY2026 revenue of $25.3B, up 6.6% year over year on 5.6% operational growth, while net income was essentially flat at $5.5B as STELARA biosimilar pressure, higher commercial spending, restructuring, and litigation-related charges offset broad product and MedTech growth. Source: 10-Q Item 2 MD&A, pp.32, 38-42; 10-Q Income Statement (XBRL).
EPS Estimate
$3.08
Revenue Estimate
$25.56B
Analyst consensus from Finnhub. Actual results posted within minutes of the SEC filing on the JNJ page.
Drawn from management commentary in the Q2 2026 10-Q:
Worldwide Q2 FY2026 sales were $25.3B, up 6.6% year over year, consisting of 5.6% operational growth and a 1.0% favorable currency impact. Innovative Medicine sales increased 7.8% to $16.4B, while MedTech sales increased 4.5% to $8.9B; U.S. sales grew 7.3% and international sales grew 5.7%.
Management said the decline in STELARA reduced worldwide operational sales growth by approximately 4.6 percentage points in Q2 FY2026. STELARA sales fell 55.2% year over year to $740M, while the broader Immunology therapeutic area declined 3.7% to $3.8B; management expects STELARA biosimilars to continue negatively affecting sales.
Oncology sales grew 17.3% to $7.4B in Q2 FY2026, including DARZALEX sales of $4.2B, up 18.9%, and CARVYKTI sales of $657M, up 49.4%. Neuroscience grew 14.0% to $2.3B, supported by SPRAVATO, up 40.8% to $584M, and CAPLYTA, up 70.9% to $361M.
Revenue
$25.31B
++6.60% YoY
EPS (Basic)
$2.30
0.00% YoY
Gross Margin
68.2%
++0.32% YoY
Add JNJ to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.